Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: bispecific antibody-drug conjugate produced by conjugating an asymmetric bispecific antibody against human EGFR and TROP2 to a DNA topoisomerase I inhibitor payload
Date Designated: 05/12/2026
Orphan Designation: treatment of gastric cancer
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Room 301, Building C29, No.218 Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu 215123
China

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-